Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Since the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
The service has already been initiated in Maharashtra but being net-based it is easily available for patients all across the country
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
Expanded EUA includes both treatment of patients with Covid-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients
Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively
A final decision regarding the approval of Ronapreve is expected from the European Commission shortly
Subscribe To Our Newsletter & Stay Updated
